SCHEMBL5338327

SCHEMBL5338327

CCN(CC)C(=O)c1ccnc(NC(=O)Nc2csc(Cl)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
GRM5 P41594 1/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 1/20 0.39
CDK5 Q00535 4/20 0.39
CDK5R1 Q15078 4/20 0.39
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
CCNA1 P78396 2/20 0.39
EGFR P00533 1/20 0.39
P2RY1 P47900 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP3A5 P20815 1/20 0.38
KDM5A P29375 1/20 0.38
KDM5C P41229 1/20 0.38
KDM5B Q9UGL1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5347302 0.89 HPGD (0.40) ALDH1A1MAPTL3MBTL1HSP90AA1HSP90AB1
SCHEMBL5342834 0.85 CDK5 (0.57) ALDH1A1MAPTL3MBTL1HPGDCDK5
SCHEMBL5342342 0.84 CDK5 (0.54) ALDH1A1MAPTHPGDLMNACDK5
SCHEMBL5343009 0.75 PROKR1 (0.44) GRM5HPGDCDK2CYP3A4PIK3C3
SCHEMBL11476352 0.74 P2RY1 (0.44) L3MBTL1CDK5CDK5R1CCNA2CDK2
SCHEMBL9321390 0.72 ALDH1A1 (0.58) ALDH1A1MAPTL3MBTL1HSP90AA1HSP90AB1
SCHEMBL5808527 0.70 ALDH1A1 (0.69) ALDH1A1MAPTL3MBTL1HSP90AA1HSP90AB1
SCHEMBL5354095 0.70 CDK5 (0.46) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5338578 0.68 CDK5 (0.40) L3MBTL1HPGDCDK5CDK5R1NPC1
SCHEMBL12677925 0.67 HPGD (0.56) ALDH1A1MAPTL3MBTL1HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1483263-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2004-12-08 EP disclosed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 US disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
WO-2003070727-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2003-08-28 WO disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX ALDH1A1 810/4885MAPT 1437/4885L3MBTL1 854/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX ALDH1A1 810/4885MAPT 1437/4885L3MBTL1 854/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX ALDH1A1 810/4885MAPT 1437/4885L3MBTL1 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.